Dr. Amy O. Chonghasawat, MD

Dr. Chonghasawat practices at Advance Surgeons Medical Group Inc in Alhambra, California.

Dr. Chonghasawat's NPI, 1003306739, was assigned on May 17, 2018. Dr. Chonghasawat graduated from WMed in 2018. Dr. Chonghasawat holds California license 186004.

Dr. Chonghasawat's primary practice is Advance Surgeons Medical Group Inc, at 328 S 1st St, Alhambra, CA 91801 in Los Angeles County. The practice phone is (626) 457-6333.

Dr. Chonghasawat's primary practice is Advance Surgeons Medical Group Inc in Alhambra, California. Dr. Chonghasawat is also affiliated with Alhambra Hospital Medical Center. The medical group on file is Advance Surgeons Medical Group. Dmand AI also links Dr. Chonghasawat to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chonghasawat practices, 6 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Chonghasawat's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dmand AI has Dr. Chonghasawat's licenses on file in 2 states: California and Michigan.

Dmand AI lists hemorrhoids among the conditions Dr. Chonghasawat treats.

CMS data shows 112 Medicare services from Dr. Chonghasawat across 6 procedure codes in 2024, for 81 Medicare patients. Medicare paid $11,693 for them.

CMS counts 81 Medicare patients who saw Dr. Chonghasawat in 2024. The largest group is 75 to 84, with 26 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 86% are also on Medicaid. Their average risk score is 2.14, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chonghasawat's median patient age at 56, with 65% women.

In 2024, Dr. Chonghasawat wrote 38 Medicare Part D claims for 17 patients. 100% of them were for generic drugs. CMS names the drug for 28 of them, across 2 drugs with 11 or more claims each, at $51 in total drug cost. In 2023, CMS named 12 claims across 1 drug.

Dr. Chonghasawat accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 13 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Chonghasawat, more than 45% of the clinicians it reports for that procedure.

Colonoscopy: 1 to 10 procedures (CMS shows small counts as a range)

Hernia repair - groin (open): 1 to 10 procedures (CMS shows small counts as a range)

Mastectomy: 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 1 paper to Dr. Chonghasawat in 2017. Dr. Chonghasawat's most frequent co-author is Alex Y. Chen, MD.

Dmand AI links Dr. Chonghasawat to 10 clinical trials, 4 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Adenocarcinoma of Lung, Biliary Atresia and Low Back Pain.

CMS Open Payments shows 2 general payments to Dr. Chonghasawat from 2 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 100% of the total. Medtronic, Inc. paid the most, $147.

Dr. Chonghasawat graduated from WMed in 2018.

Dr. Chonghasawat is in network with 12 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.